US BARDA funds Sanofi's 43.2 million US dollars to promote Zika vaccine into Phase II clinical development
US BARDA funds Sanofi's 43.2 million US dollars to promote Zika vaccine into Phase II clinical development
October 09, 2016 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];In July of this year, Sanofi Pasteur and the US Walter Reed Army Research Institute (WRAIR) reached a cooperative research and development agreement to jointly develop a Zika vaccine candidate. The funding provided by BARDA will promote WRAIR's Zika IV Inactivated Virus (ZPIV) vaccine into Phase II clinical development, including the production of clinical vaccines in line with current GMP to support Phase II clinical trials, optimizing upstream processes to increase yield and vaccines. Product characteristics.
Sanofi Pasteur is responsible for the development of the clinical development and management strategy for Zika vaccine, while WRAIR and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) are conducting a series of Phase I ZPIV clinical trials. test. In addition to funding two Phase I/II clinical trials, BARDA also has the option to continue funding for Phase III industrialization and clinical development.
WRAIR will share data related to the development of immunoassays designed to detect natural infections and neutralizing antibody responses following ZPIV vaccination, biological samples obtained in non-human primate studies, and in the use of ZPIV Biological samples obtained from studies of human safety and immunogenicity in vaccines.
Currently, Sanofi is also conducting its in-house preclinical research using the technology previously used to successfully develop dengue vaccines and Japanese encephalitis vaccines. Zika virus, dengue fever, and Japanese encephalitis all belong to the same virus family (viral family), which are transmitted by the same type of mosquitoes and have some similarities in genetics. Previously, the company said in February that after experiencing the successful development of dengue vaccine, many experiences can help understand the spread of Zika virus, and provide ideas for developing potential vaccine candidates to resist the infection and spread of Zika virus.
Tylvalosin Tartrate,Tylvalosin Premix,Tylvalosin Veterinary Drug,Tylvalosin Tartrate Pig
Shandong Shengli Bioengineering Co., Ltd , https://www.shenglipharm.com